Baseline characteristics and enrichment results from the SONAR trial

AIM: The SONAR trial uses an enrichment design based on the individual response to the selective endothelin receptor antagonist atrasentan on efficacy (the degree of the individual response in the urinary albumin‐to‐creatinine ratio [UACR]) and safety/tolerability (signs of sodium retention and acut...

Descripción completa

Detalles Bibliográficos
Autores principales: Heerspink, Hiddo J.L., Andress, Dennis L., Bakris, George, Brennan, John J., Correa‐Rotter, Ricardo, Hou, Fan Fan, Kitzman, Dalane W., Kohan, Donald, Makino, Hirofumi, McMurray, John, Perkovic, Vlado, Tobe, Sheldon, Wigderson, Melissa, Yi, Tingting, Parving, Hans‐Henrik, de Zeeuw, Dick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2018
Materias:
Clinical Trial Design
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055730/
https://www.ncbi.nlm.nih.gov/pubmed/29604160
http://dx.doi.org/10.1111/dom.13315

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055730/
https://www.ncbi.nlm.nih.gov/pubmed/29604160
http://dx.doi.org/10.1111/dom.13315

Ejemplares similares